title: PROPORTION OF PATIENTS WITH MACULAR HOLE SURGERY WHO WOULD HAVE BEEN FAVORABLE OCRIPLASMIN CANDIDATES: A Retrospective Analysis.
abstract: OBJECTIVE
  To identify favorable ocriplasmin candidates from a cohort of idiopathic full thickness macular hole surgery patients.
  
  
  METHODS
  The records of patients with full thickness macular hole who underwent pars plana vitrectomy surgery between 2011 and 2015 were reviewed. Clinical data collected included patient demographics, pre- and post-operative Snellen visual acuity, optical coherence tomography findings, and lens status. The authors defined "favorable" ocriplasmin candidates as patients with focal vitreomacular traction, no epiretinal membrane, and hole size ≤400 μm. The authors further categorized "optimal" candidates as age ≤65, phakic, no epiretinal membrane, with focal vitreomacular traction, and hole size ≤400 μm.
  
  
  RESULTS
  The records of 238 patients were assessed; 30.7% were male while mean age was 68.6 ± 8.3 years. The mean logMAR acuity was 1.2 (Snellen 20/317) preoperatively and 0.90 (Snellen 20/159) postoperatively. Optical coherence tomography findings indicated that 46.5% of the macular holes studied were less than ≤400 μm in size, 14.8% had an epiretinal membrane, and 25.3% had vitreomacular traction. A total of 17.7% of study patients were found to be favorable candidates, whereas 3.8% were optimal ocriplasmin candidates.
  
  
  CONCLUSIONS
  Only a minority of full thickness macular hole surgical candidates in this cohort would be considered favorable ocriplasmin candidates.
authors.affiliation: *Department of Ophthalmology, St. Michael's Hospital, Toronto, Ontario, Canada;†Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; and‡Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Khurram
authors.initials: K
authors.lastname: Chaudhary
authors.forename: Michael Y K
authors.initials: MY
authors.lastname: Mak
authors.forename: Robert
authors.initials: R
authors.lastname: Gizicki
authors.forename: Rajeev H
authors.initials: RH
authors.lastname: Muni
authors.forename: David T
authors.initials: DT
authors.lastname: Wong
authors.forename: Filiberto
authors.initials: F
authors.lastname: Altomare
authors.forename: Alan R
authors.initials: AR
authors.lastname: Berger
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019773:Epiretinal Membrane / Q000473:pathology; D005260:Female; D005341:Fibrinolysin / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use*; D019591:Pseudophakia / Q000473:pathology; D012167:Retinal Perforations / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014792:Visual Acuity; D014821:Vitrectomy / Q000379:methods
chemical_list: D005343:Fibrinolytic Agents; D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin